Argenx SE: Strong Buy Rating on Vyvgart’s Market Expansion and Promising Pipeline
TipRanks (Wed, 15-May 5:38 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 14-May 7:10 AM ET)
TipRanks (Mon, 13-May 11:30 AM ET)
TipRanks (Mon, 13-May 7:10 AM ET)
Stifel Nicolaus Keeps Their Buy Rating on Argenx Se (ARGX)
TipRanks (Sun, 12-May 10:07 PM ET)
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Thu, 9-May 1:00 AM ET)
argenx announces results of Annual General Meeting of Shareholders
Globe Newswire (Tue, 7-May 5:30 PM ET)
argenx to Present at BofA Securities 2024 Health Care Conference
Globe Newswire (Tue, 7-May 1:00 AM ET)
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
Globe Newswire (Thu, 2-May 1:00 AM ET)
Globe Newswire (Tue, 16-Apr 1:00 AM ET)
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Argenx Se - American Depositary Shares trades on the NASDAQ stock market under the symbol ARGX.
As of May 16, 2024, ARGX stock price declined to $376.30 with 82,648 million shares trading.
ARGX has a beta of 0.95, meaning it tends to be less sensitive to market movements. ARGX has a correlation of 0.05 to the broad based SPY ETF.
ARGX has a market cap of $22.36 billion. This is considered a Large Cap stock.
Last quarter Argenx Se - American Depositary Shares reported $398 million in Revenue and -$1.04 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.28.
In the last 3 years, ARGX stock traded as high as $550.76 and as low as $249.50.
The top ETF exchange traded funds that ARGX belongs to (by Net Assets): IBB, FBT, BBH, QQQJ, TCAF.
ARGX has underperformed the market in the last year with a price return of -7.3% while the SPY ETF gained +29.8%. ARGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.4% and -1.8%, respectively, while the SPY returned +5.8% and +5.8%, respectively.
ARGX support price is $368.42 and resistance is $385.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARGX stock will trade within this expected range on the day.